Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

被引:83
|
作者
Ganbaatar, Byambasuren [1 ]
Fukuda, Daiju [2 ]
Shinohara, Masakazu [3 ,4 ]
Yagi, Shusuke [1 ]
Kusunose, Kenya [1 ]
Yamada, Hirotsugu [5 ]
Soeki, Takeshi [1 ]
Hirata, Ken-ichi [6 ]
Sata, Masataka [1 ]
机构
[1] Tokushima Univ, Dept Cardiovasc Med, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[2] Tokushima Univ, Dept Cardiodiabet Med, Grad Sch Biomed Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
[3] Kobe Univ, Integrated Ctr Mass Spectrometry, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[4] Kobe Univ, Div Epidemiol, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[5] Tokushima Univ, Dept Community Med Cardiol, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[6] Kobe Univ, Div Cardiovasc Med, Grad Sch Med, Kobe, Hyogo 6500017, Japan
关键词
Atherosclerosis; Inflammation; Endothelial function; SGLT2; inhibitor; Empagliflozin; PERIVASCULAR ADIPOSE-TISSUE; SGLT2; INHIBITOR; MORTALITY; ATHEROSCLEROSIS; PHENOTYPE; DISEASE; ROLES; AGES;
D O I
10.1016/j.ejphar.2020.173040
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE(-/-)) mice. Male streptozotocin (STZ) - induced diabetic ApoE(-/-) mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE / mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E-2 and thromboxane B-2 (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-alpha in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE(-/-) mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Hypercholesterolemia promotes early renal dysfunction in apolipoprotein E-deficient mice
    Camille M Balarini
    Mariana ZT Oliveira
    Thiago MC Pereira
    Nyam F Silva
    Elisardo C Vasquez
    Silvana S Meyrelles
    Agata L Gava
    Lipids in Health and Disease, 10
  • [42] Hypercholesterolemia promotes early renal dysfunction in apolipoprotein E-deficient mice
    Balarini, Camille M.
    Oliveira, Mariana Z. T.
    Pereira, Thiago M. C.
    Silva, Nyam F.
    Vasquez, Elisardo C.
    Meyrelles, Silvana S.
    Gava, Agata L.
    LIPIDS IN HEALTH AND DISEASE, 2011, 10
  • [43] Effects of Simvastatin on adiponectin and endothelial function in apolipoprotein E-deficient mice
    Meng LiuDonghua YinMing GuiKejiang Cao Department of CardiologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjing China
    Journal of Nanjing Medical University, 2009, 23 (01) : 46 - 49
  • [45] Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice
    Masliah, E
    Armasolo, F
    Veinbergs, I
    Mallory, M
    Samuel, W
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1999, 62 (02) : 239 - 245
  • [46] Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice
    Lin, RY
    Choudhury, RP
    Cai, WJ
    Lu, M
    Fallon, JT
    Fisher, EA
    Vlassara, H
    ATHEROSCLEROSIS, 2003, 168 (02) : 213 - 220
  • [47] Role of angiotensin IV on endothelial function in apolipoprotein E-deficient mice
    Vinh, A
    Widdop, RE
    Gaspari, TA
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (07) : A47 - A47
  • [48] Systemic Delivery of Microrna-146a Improves Endothelial Function and Ameliorates Atherosclerosis in Apolipoprotein E-deficient Mice
    Ma, Shuangtao
    Tian, Xiao Yu
    Mu, Chaofeng
    Shen, Haifa
    Zhang, Yunrong
    Bismuth, Jean
    Wong, Wing Tak
    CIRCULATION RESEARCH, 2015, 117
  • [49] NADPH-oxidase as a source of superoxide causing endothelial dysfunction in atherosclerotic apolipoprotein E-deficient mice
    Dusting, GJ
    Drummond, GR
    Dang, TT
    Gulluyan, LM
    JOURNAL OF HYPERTENSION, 2002, 20 : S11 - S11
  • [50] Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
    d'Uscio, LV
    Barton, M
    Shaw, S
    Lüscher, TF
    CARDIOVASCULAR RESEARCH, 2002, 53 (02) : 487 - 495